Next generation targeted protein therapeutics

Latest News
11/07/2013 ImmunGene Raises $9 Million in Series A Financing
06/03/2013 ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
05/22/2013 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
11/13/2012 Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine

ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology

ImmunGene Receives $244,479 Grant Under The Patient Protection And Affordable Care Program For Its Anti-Cancer Technology
ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today

                             Antibody-based therapeutics
                                                 to treat cancer,
                              autoimmune and other disease

Welcome to ImmunGene

ImmunGene is a privately held drug discovery and development company, developing next generation of monoclonal antibody-based therapeutics to treat cancer, autoimmune disorders and other diseases.
Our focus

ImmunGene is working to make our novel drug candidates for treating diseases that affect tens of millions of people worldwide. ImmunGene's primary focus is on safe and effective treatments for cancer.

ImmunGene also has programs underway to treat other potentially devastating diseases, including infections.
Our approach

ImmunGene is leveraging promising science to tap the power of the immune systems to develop therapeutic antibodies that are highly optimized for efficacy and a superior safety profile.

Our technology allows us to fuse cytotoxic cytokines to antibodies to selectively target disease causing cells and tissues while reducing the systemic toxicity of the cytokines.